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population would be ca 130,000,000 PLN in 2011 and will steadily increase to ca
202,000,000 PLN in 2015. In case of tenofovir reimbursement estimated decrease in
total expenditures will be ca 6,000,000 PLN in 2011 and ca 11,000,000 PLN in 2015.
CONCLUSIONS: The decision for tenofovir reimbursement will cause decrease in
public payer expenditures for patients with chronic hepatitis B.
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OBJECTIVES: Budget impact analysis of chronic hepatitis (HCV) pharmacotherapy
with pegylated interferon alfa-2a (PegIFN alfa-2a) and pegylated interferon alfa-2b
(PegIFN alfa-2b).METHODS: The study used a Budget Impact Analysis method with
the Rational Drug Use Indicator (RDUI), which allows to quantitatively describe the
economic effectiveness of a particular drug taking into account its useful applica-
tion potential. The modeling was based on the data collected in IDEAL clinical
study. The model considered two groups of HCV genotype 1 patients, equal in
number (1000 patients per group) and comparable in demographic, clinical, and
virological characteristics: group 1 – patients receiving PegIFN alfa-2a, group 2 –
PegIFN alfa-2b. Patients’ age and weight, as well as the drug dose were taken into
account. A sensitivity analysis was performed in modeling the number of patients
treated with PegIFN alfa-2a and PegIFN alfa-2b. RESULTS: It is estimated that under
the given model conditions the direct costs per patient in PegIFN alfa-2a treatment
of hepatitis C for 48 weeks amounted to 419,199.36 rubles, and PegIFN alfa-2b –
422,637.12. The direct costs difference in the 1: 1 ratio of patients treated with
PegIFN alfa-2a and PegIFN alfa-2b amounted to 1,718,880 rubles. As shown by the
RDUI calculation, inefficient budget expenditure in the case of using PegIFN alfa-2b
in 1,000 patients during the analyzed treatment period may reach 63,395,570 ru-
bles. The results sensitivity analysis according to RDUI revealed a dependence of
the budget losses on the share of patients receiving PegIFN alfa-2a and PegIFN
alpha-2b. CONCLUSIONS: When comparing the budget impact by PegIFN alfa-2a
and PegIFN alfa-2b HCV treatment strategies, the economic expediency of the
strategy of using PegIFN alfa-2a in Russian patients was identified.
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OBJECTIVES: This study aimed to assess the efficiency of the 13-valent pneumococcal
conjugate vaccine (PCV13) administered annually to 65-years-old cohort in Spain versus
the alternative of not vaccinating and treating patients only when infected. METHODS:
Infections avoided were calculated through a dynamic model based on Anderson
and May work. 70% of the 65-years-old cohort was assumed as vaccinated with one
PCV13 dose (318,000 subjects). Basecase estimated vaccine efficacy and serotype
coverage were as follows (75% and 70% respectively). Disease cost was calculated
based on CMBD database and published data. RESULTS: During the 5 years frame,
a total of 83,844 infections would be avoided. Net savings of €62 million would be
obtained. The distribution of the savings was not homogeneous, starting in the 3rd
and increasing until the 5th year. To demonstrate model robustness, analyses of
additional scenarios have been performed using extreme values of model param-
eters (vaccination programme coverage, vaccine efficacy, serotype coverage). Un-
der those scenarios, the net savings results were always achieved. CONCLUSIONS:
After three years, 65-year-cohort pneumococcal vaccination campaign appeared to
be a cost saving intervention among Spanish population under different scenarios.
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OBJECTIVES: Evaluation of comparative cost-effectiveness of treatment of CAP
complicated by sepsis with moxifloxacin compared to ceftriaxone  azithromycin
in adult patients. METHODS: literature search revealed prospective non-random-
ized comparative controlled clinical trial (n87) where treatment efficacy of CAP
complicated by sepsis was evaluated. MOX group received moxifloxacin (400 mg
i.v.) 3-4 days with further switch to 400 mg per os daily. CEAZ group received
combined therapy with ceftriaxone 2000 mg i.v. and azithromycin 5000 mg during
5 days. Efficacy criteria were length of antibacterial treatment, ICU and in-hospital
days. Cost-effectiveness analysis was performed. RESULTS: Patients of MOX group
spent 2.71.3 ICU days compared to 3.91.4 days (p0.05) in CEAZ group. Antimi-
crobial treatment took 7.00.4 days in MOX and 10.00.5 days in CEAZ group
(p0.05). There was not statistically significant deference in hospital days. Costs of
antibacterial treatment and ICU stay were 17,803 RUR (€447) per patient in MOX
group and 19,020 (€478) in CEAZ group. CONCLUSIONS: treatment of CAP compli-
cated by sepsis with moxifloxacin compared to combined therapy in adult patients
leads to ICU stay reduction by 1.2 days and cost saving by 1216 RUB (€31).
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OBJECTIVES: The objective was to compare two modeling approaches to estimate
the future burden of hepatitis C in selected countries. Due to varying efficacy de-
pending on host factors such as viral load at baseline, disease duration, pre-treat-
ment status, and disease severity more complex modeling is required. METHODS:
Two models were developed. Model A was based on a classic Markov model with
seven disease states modeling the impact of the new drugs based on response-
guided therapy and efficacy. Drug acquisition cost, treatment management and
annual health care cost were determined and the potential budget impact was
assessed. Several “what if” analyses were performed. Model B is a dynamic, indi-
vidual-based, stochastic model providing a powerful tool to perform sensitivity
analysis on uncertain and disputed parameters. All input variables (incidence,
prevalence, genotype distribution, cost, drug efficacy) were derived from a system-
atic literature and database review and analysis. RESULTS: In “what if” scenarios
with varying treatment rates the time and cost to potential elimination of hepatitis
C were modeled. Assuming all patients currently infected with hepatitis C would be
treated from 2012 onwards, with efficacies (SVR) ranging between 70% and 80%,
and assuming constant infection rates resulted in elimination of hepatitis C by the
year 2030 in model A. In model B, in which individual-based host factors were taken
into account, elimination was not achieved in the same time period. Different
“what if” scenarios for non-responders, variations in baseline host factors, poten-
tial relapses and development of resistance were modeled more reliable with the
individual-based model. CONCLUSIONS:Modeling “what if” scenarios on the basis
of expected drug efficacy utilizing a dynamic, individual-based stochastic model
results in a more comprehensive tool to estimate the distribution of expected
future burden of HCV.
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OBJECTIVES: The epidemiological transition for HIV-infection from a fatal condi-
tion to a chronic disease, has significant impact on decision-making process to
ensure therapy appropriateness and to monitor the rising costs of antiretroviral
(ARV) therapy. Starting from Lombardy Region’s MOLO Project (MOnoterapia LOpi-
navir), this analysis aims to develop a methodological model based on treatment
appropriateness, and to carry out an impact assessment of the simplification to
monotherapy with lopinavir/ritonavir for HIVpatients vs. standard therapy (NRTI
backbone plus a third agent). METHODS: From the cohort of 23,721 HIV patients,
according to eligibility criteria of 2010 Italian Guidelines, a static and dynamic (5ys)
decisional model was produced to study the evolution of the disease, correlating
clinical developments with total costs of population under assessment. The model
provides 2 possible scenarios: monotherapy control or failure leading to re-induc-
tion. Cost of medicines, DRGs, lab tests and all other costs were inputted. The
budget impact analysis was completed with an impact assessment comprehensive
of: cost-effectiveness analysis, organizational, ethics and equity impact of treat-
ment options. RESULTS: The analysis showed that the simplification to mono-
therapy with lopinavir/ritonavir could affect a significant sector of HIV patients,
bringing economic benefits from 10.7 to 21.6MM€, in the first year. Analyzing the
entire diagnostic clinical pathway, the analysis showed savings of 10.8 to 22.6MM€,
and of 47.6 to 144.8 MM€ from 2,011 to 2,016. Monotherapy with lopinavir/ritonavir
also ensures a better result vs. standard in terms of cost-effectiveness (14.007€ vs.
11.673€ in the most conservative hypothesis). Organizational impact doesn’t show
any differences between the two approaches, ethical impact is positive to the pa-
tients as regards long-term toxicity. CONCLUSIONS: The result of the analysis
suggests that national and regional decision makers have considerable space for
maneuver into a more appropriate position for resources management, without
changing the efficacy and safety results of patients.
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OBJECTIVES: The Veterans Health Administration (VHA) is the largest single pro-
vider of hepatitis C (HCV) care in the United States. The newly approved direct
acting antivirals (DAAs), Boceprevir (BOC) and Telaprevir (TEL) have significantly
improved SVR rates for HCV Genotype 1 (GT1) patients. The objective was to project
potential costs of DAAs on GT1 patients in the VHA.METHODS:A decision-analytic
Markov model was developed to simulate the lifetime progression of HCV disease
and to estimate the costs and clinical impacts of DAA in the current cohort of
103,331 GT1 treatment-naïve patients. Estimated federal pricing for drug costs and
published response-guided antiviral efficacy data were used in the model. Treat-
ment costs included drugs, inpatient/outpatient visits, and laboratory tests. We
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estimated cost and effectiveness for four treatment strategies: 1) Standard dual
therapy pegylated interferon alfa and ribavirin (PR); 2) BOCPR triple therapy; 3)
TELPR triple therapy; and 4) no treatment. RESULTS: In our model, patients re-
ceived 1) PR for 48 weeks; 2) TEL for 12 weeks with PR for 34-36 weeks; or 3) BOC for
29 weeks with PR for 34-36 weeks. Estimated treatment cost associated with PR
alone, BOCPR, and TELPR are about $8,300, $31,000 and $45,000 per average
patient, respectively. Total system-wide costs to adopt BOCPR or TELPR would
be $673 million and $971 million, respectively. Assuming continuation of the cur-
rent 21% VHA treatment rates and optimal SVR results, the long term reduction in
liver related death from treatment PR, BocPR, and TelPR are 7.9%, 13.1%, and
14.5%, respectively.CONCLUSIONS:Our model indicates upfront investments with
BOCPR, and TELPR are high, with the benefits of extending quality of life and
lower costs due to liver-related morbidity. Though model projected potential cost
under these assumptions, a clinical trial of comparative effectiveness would be
needed to evaluate both costs and benefits of DAAs in veterans.
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OBJECTIVES: In Brazil, switching to a protease inhibitor (PI) based ARV regimen is
recommended as second line therapy for experienced patients failing non-nucle-
oside reverse transcriptase inhibitors. The BMS-045 study compared ATVRTV
and LPV/r regimens in ARV-experienced patients. Similar viral load (VL) suppres-
sion rates 400 copies were reported, but LPV/r provided greater suppression rate
50 copies. Total cholesterol (TC) levels improved to guideline levels in 23% of
ATVRTV patients and became elevated in 7% of LPV/r patients at 48 weeks. The
long term clinical and cost impact of this difference is not yet clear. The objective of
this study was to examine the long term HRQL and economic implications in Brazil
for LPV/r versus ATVRTV treatment of ARV-experienced patients. METHODS: A
previously published HIV Markov model was adapted. Baseline assumptions: TC
profile and CD4 cell distribution matching the BMS-045 population. HRQL and sur-
vival outcomes were measured in quality adjusted life years (QALYs). Costs in
Brazilian Reale were indexed to 2011. ARV costs and HIV treatment patterns were
based on Brazilian references. Lifetime costs/outcomes were discounted at 3% per
annum. A national health services perspective was adopted. RESULTS:VL suppres-
sion differences favored LPV/r, driving a net improvement in survival (0.31 QALYs,
106 days). Five and 10 year cost savings (BRL1,816, BRL1,496 per patient) were pro-
jected for LPV/r. Lifetime costs were slightly higher for LPV/r due to improved
survival. An incremental cost effectiveness ratio (ICER) of BRL2319 per QALY gained
was estimated for the LPV/r regimen, which is highly acceptable by Brazilian
threshold . CONCLUSIONS: Compared to ATVRTV, an LPV/r based regimen is cost
saving through the first 10 years of survival and is a cost effective use of public
resources for ARV-experienced Brazilian patients. LPV/r implementation is sup-
ported by its improved viral suppression, short/long term cost savings and favor-
able ICER.
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OBJECTIVES: Research data on antibiotic usage pattern and cost comparison are
scant in our country. Therefore we planned to identify oral antibiotic (OA) con-
sumption and cost comparison for 2010 in tertiary care hospital in Sri Lanka.
METHODS: Aggregate data for 2010 was collected from records of pharmacy and
unit price was obtained from medical supplies division. Initial and final stocks of
the OA, quantity received, quantities issued, quantity consumed and hospital data
from VEN analysis were obtained. We identified the top ten for total cost (TTTC)
and top ten for consumption (TTCS) OA. RESULTS: Ninethy-three percent of total
cost for TTTC was utilized for the top seven highly consumed OA with low unit
price. Seven percent of TTTC had been utilized for the drugs which were not in
TTCS. In contrast three drugs in TTCS had not been included in TTTC but in the list
of top 20. Low quota ( 2.5%) of the TTTC had been utilized for non essential drug in
VEN which was not even in TTCS of OA. CONCLUSIONS: Ninety-three percent of
the cost has been effectively utilized highly consumed low cost OA in this hospital
for 2010. Seven percent of money in TTTC was spent for expensive OA. We suggest
the authority to reconsider the change the drug ordering pattern with minimum
cost and to suitable alternative low cost generics instead of expensive product.
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OBJECTIVES: We planned to identify the 2010 parenteral antibiotic (PA) consump-
tion pattern and its cost effectiveness in government teaching hospital using ag-
gregate data. METHODS: Aggregate data for 2010 was collected from pharmacy
records and unit prize was obtained from medical supplies division. Initial and final
stocks of the OA, quantity received, quantities issued and consumed per year were
obtained. Data for VEN analysis was collected. Data was analyzed to identify the
top ten for total cost (TTTC) and top ten for consumption (TTCS) PA according to the
total cost and the consumption separately. RESULTS: Ninety-three perecent of
TTTC was utilized for the top 7 highly consumed OA with low unit prize. Seven
percent of expenditure of TTTC was utilized for drugs which were not included in
TTCS. In contrast 3% of drugs (3 OA) in TTCS had not been included in TTTC. This
indicates that these three OAs are cost effectively used. 2.5% of the TTTC had been
used for a non essential drug in VEN which was not included even in TTCS of OA.
CONCLUSIONS: We conclude that 93% of the cost has been effectively utilized
highly consumed low cost OA in this hospital for 2010. Seven percent of the TTTC
had been spent for expensive oral antibiotics. We suggest the authority to recon-
sider the change the drug orders to maximize the cost effectiveness and prioritize
alternative low cost generics instead of expensive product orders.
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OBJECTIVES: One third of skin and soft tissue infections (SSTI) are caused by me-
thicilin-resistant staphylococcus aureus (MRSA). This study aims to compare SSTI-
MRSA treatment costs with linezolid versus branded and generic vancomycin un-
der the Brazilian private payer perspective. METHODS: A cost comparison study
was performed to compare linezolid versus generic and branded vancomycin. As
supported by clinical studies, overall treatment duration of 15 days with linezolid
and 14 days with vancomycin was considered, using PO linezolid after a minimum
4-days cycle of IV infusion while vancomycin (1g bid) was entirely IV. A decision-
tree model simulated SSTI-MRSA treatment assuming linezolid (600mg bid) IV can
be switched to PO after 4-days and patients can be discharged if PO is implemented
at physician discretion. Length of stay (LOS) and IV linezolid duration were ranged
in one-way sensitivity analysis. Only direct medical costs were included in the
analysis (hospital charges, medical visits, medical supplies and drug acquisition
costs) and unit costs were obtained from Brazilian official price lists (2010 USD
values). RESULTS: The linezolid scheme with 4-days IV (LOS4 days) and 11-days
PO resulted in overall costs per patient of 4089.58 USD, while branded and generic
vancomycin exhibited 6657.33 USD and 6970,23 USD, respectively. The incremental
cost of vancomycin-treated patients was driven by hospital daily charges, respon-
sible for over 55% of the overall vancomycin costs. One-way sensitivity analysis
revealed cost-savings for linezolid up to LOS 12 days, with overall costs per pa-
tient ranging from 4089.58 to 7428.84 USD if IV therapy was maintained throughout
the inpatient period (LOS15 days). CONCLUSIONS: Linezolid exhibited a cost-
saving profile over branded or generic vancomycin for the treatment of SSTI-MRSA
under the Brazilian public payer perspective. This economic benefit was a direct
result of potential early discharge of patients receiving PO linezolid.
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OBJECTIVES: Voriconazole (VOR) demonstrated better tolerability with a longer
treatment duration and less concomitant systemic antifungal drugs (con AF) com-
pared to itraconazole (ITR). This study assessed key cost components associated
with prophylaxis treatment of IFI after allogeneic HSCT across 4 countries (Canada,
France, Germany, and US). METHODS: A prospective open-label multicenter clini-
cal trial (IMPROVIT) for primary IFI prophylaxis after HSCT included patients12
years who were randomized to oral VOR or oral ITR from HSCT day for at least 100
and up to 180 days. Trial data on the key medical resource utilization (including
hospital days and con AF use) for the first 100 days were analyzed and valued in
2010 costs. RESULTS:A total of 224 patients were in VOR and 241 in ITR group, with
similar demographics (average age 43-year, 59% male, 92% Caucasian). VOR pa-
tients (vs. ITR) had longer study drug exposure (median: 96 vs. 68 days, p0.0001;
mean: 68 vs. 60 days, p0.0162) and were 2 times less likely (P0.0032) to use con
AF. The average per-patient hospital cost for voriconazole (vs. itraconazole) was
Can$27,674 (vs. Can$29,669), €13,277 (vs. €13,632), €15,185 (vs. €15,762), and $31,916
(vs. $33,521) in Canada, France, Germany, and the U.S., respectively. The average
per-patient cost of con AF for voriconazole (vs. itraconazole) was Can$1028 (vs.
Can$2290 p0.0061), €2208 (vs. €4678, p0.0095), €2422 (vs. €5033, p0.0177), and
$1,720 (vs. $3612, p0.0146) in the study countries respectively. Total costs varied
by country and were similar between treatment groups. The mean difference of 8
days in prophylaxis days between VOR and ITR was associated with 3.54%-4.55%
reduction (depending on the country) in inpatient cost (all p.0001) and 9.13%-
11.82% reduction in con AF cost (all p.01). CONCLUSIONS: Better tolerability of IFI
prophylaxis after HSCT was associated with cost offsets due to reduced hospital-
ization and concomitant antifungal use.
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QUANTIFYING THE FINANCIAL AND DISEASE BURDEN ASSOCIATED WITH
MOTHER TO CHILD TRANSMISSION OF HIV IN UGANDA
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